| Theme |
Acute Liver Injury ： Drug-induced and Viral Liver Injuries |
| Title |
Treatment for Drug-induced Liver Injury |
| Author |
Yasushi Matsuzaki |
Department of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center |
| Author |
Tadashi Ikegami |
Department of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center |
| [ Summary ] |
Regarding treatment for drug-induced liver injury, the most important aspect is early recognition and discontinuation of the presumed causative agent. In Japan, ursodeoxycholic acid (UDCA) and glycyrrhizin (SNMC) are used for the drug-induced hepatotoxicity and cholestasis. UDCA is safe and well tolerated. At the same time, a short course of corticosteroid treatment is used for prolonged drug-induced cholestasis. Recently, it has been found that the efficacy of some agents for patients with drug-induced liver injury has an interpatient's variability due to the particular of individual pharmacogenomics. If the functional basis for such efficacy can be established, a firmer conceptual basis or more appropriate pharmacologic agents to obtain clinical resolution may be established. |